Published in Mol Psychiatry on March 01, 2004
Antidepressants recruit new neurons to improve stress response regulation. Mol Psychiatry (2011) 2.11
Adult hippocampal neurogenesis: regulation, functional implications, and contribution to disease pathology. Neurosci Biobehav Rev (2008) 1.77
Genome-wide epigenetic regulation by early-life trauma. Arch Gen Psychiatry (2012) 1.57
What causes the hippocampal volume decrease in depression? Are neurogenesis, glial changes and apoptosis implicated? Eur Arch Psychiatry Clin Neurosci (2007) 1.52
Corticolimbic transcriptome changes are state-dependent and region-specific in a rodent model of depression and of antidepressant reversal. Neuropsychopharmacology (2008) 1.42
Neurobiology of chronic mild stress: parallels to major depression. Neurosci Biobehav Rev (2012) 1.41
Astrocyte-derived ATP modulates depressive-like behaviors. Nat Med (2013) 1.35
Progress in corticotropin-releasing factor-1 antagonist development. Drug Discov Today (2010) 1.32
Depression, antidepressants, and neurogenesis: a critical reappraisal. Neuropsychopharmacology (2011) 1.25
Long-lasting behavioral effects and recognition memory deficit induced by chronic mild stress in mice: effect of antidepressant treatment. Psychopharmacology (Berl) (2008) 1.21
Leptin restores adult hippocampal neurogenesis in a chronic unpredictable stress model of depression and reverses glucocorticoid-induced inhibition of GSK-3β/β-catenin signaling. Mol Psychiatry (2011) 1.20
Depression: a repair response to stress-induced neuronal microdamage that can grade into a chronic neuroinflammatory condition? Neurosci Biobehav Rev (2010) 1.17
Neurogenesis and depression: what animal models tell us about the link. Eur Arch Psychiatry Clin Neurosci (2007) 1.08
Therapeutic utility of non-peptidic CRF1 receptor antagonists in anxiety, depression, and stress-related disorders: evidence from animal models. Pharmacol Ther (2010) 1.06
The effects of CRF antagonists, antalarmin, CP154,526, LWH234, and R121919, in the forced swim test and on swim-induced increases in adrenocorticotropin in rats. Psychopharmacology (Berl) (2005) 1.04
Behavioral, biological, and chemical perspectives on targeting CRF(1) receptor antagonists to treat alcoholism. Drug Alcohol Depend (2013) 1.03
Immature dentate gyrus: an endophenotype of neuropsychiatric disorders. Neural Plast (2013) 1.01
Failure to mount adaptive responses to stress results in dysregulation and cell death in the midbrain raphe. J Neurosci (2008) 1.00
The vasopressin Avpr1b receptor: molecular and pharmacological studies. Stress (2010) 0.99
Open questions in current models of antidepressant action. Br J Pharmacol (2010) 0.99
Hippocampal neurogenesis, depressive disorders, and antidepressant therapy. Neural Plast (2007) 0.98
Sustained stress-induced changes in mice as a model for chronic depression. Psychopharmacology (Berl) (2010) 0.97
Neural plasticity and proliferation in the generation of antidepressant effects: hippocampal implication. Neural Plast (2013) 0.96
Lithium, but not fluoxetine or the corticotropin-releasing factor receptor 1 receptor antagonist R121919, increases cell proliferation in the adult dentate gyrus. J Pharmacol Exp Ther (2011) 0.96
The neural plasticity theory of depression: assessing the roles of adult neurogenesis and PSA-NCAM within the hippocampus. Neural Plast (2013) 0.94
The effects of congenital brain serotonin deficiency on responses to chronic fluoxetine. Transl Psychiatry (2013) 0.92
Bipolar disorder: candidate drug targets. Mt Sinai J Med (2008) 0.90
Neurogenesis-independent antidepressant-like effects on behavior and stress axis response of a dual orexin receptor antagonist in a rodent model of depression. Neuropsychopharmacology (2012) 0.87
NF-κB mediated regulation of adult hippocampal neurogenesis: relevance to mood disorders and antidepressant activity. Biomed Res Int (2014) 0.85
Mice overexpressing corticotropin-releasing factor show brain atrophy and motor dysfunctions. Neurosci Lett (2010) 0.84
Role of sudarshan kriya and pranayam on lipid profile and blood cell parameters during exam stress: A randomized controlled trial. Int J Yoga (2012) 0.84
Long-term α1A-adrenergic receptor stimulation improves synaptic plasticity, cognitive function, mood, and longevity. Mol Pharmacol (2011) 0.84
Mifepristone prevents stress-induced apoptosis in newborn neurons and increases AMPA receptor expression in the dentate gyrus of C57/BL6 mice. PLoS One (2011) 0.84
Mechanisms of action of antidepressants: from neurotransmitter systems to signaling pathways. Cell Signal (2005) 0.82
DETA/NONOate, a nitric oxide donor, produces antidepressant effects by promoting hippocampal neurogenesis. Psychopharmacology (Berl) (2008) 0.81
Regulation of adult neurogenesis in the hippocampus by stress, acetylcholine and dopamine. J Nat Sci Biol Med (2011) 0.81
Rodent models of depression: neurotrophic and neuroinflammatory biomarkers. Biomed Res Int (2014) 0.81
Synthesis and evaluation of candidate PET radioligands for corticotropin-releasing factor type-1 receptors. Nucl Med Biol (2014) 0.80
Epigenetic (de)regulation of adult hippocampal neurogenesis: implications for depression. Clin Epigenetics (2011) 0.80
Depression-like deficits in rats improved by subchronic modafinil. Psychopharmacology (Berl) (2009) 0.78
Hippocampal and behavioral dysfunctions in a mouse model of environmental stress: normalization by agomelatine. Transl Psychiatry (2014) 0.78
Reactivation of Tert in the medial prefrontal cortex and hippocampus rescues aggression and depression of Tert(-/-) mice. Transl Psychiatry (2016) 0.76
Lasting Adaptations in Social Behavior Produced by Social Disruption and Inhibition of Adult Neurogenesis. J Neurosci (2016) 0.76
The Timing of Antidepressant Effects: A Comparison of Diverse Pharmacological and Somatic Treatments. Pharmaceuticals (Basel) (2010) 0.76
SSR149415, a non-peptide vasopressin V1b receptor antagonist, has long-lasting antidepressant effects in the olfactory bulbectomy-induced hyperactivity depression model. Naunyn Schmiedebergs Arch Pharmacol (2008) 0.76
Prevention of gallstones by Lidan Granule: Insight into underlying mechanisms using a guinea pig model. Biomed Rep (2016) 0.75
Neuroimmune Interface in the Comorbidity between Alcohol Use Disorder and Major Depression. Front Immunol (2016) 0.75
The Role of Hypothalamic Neuropeptides in Neurogenesis and Neuritogenesis. Neural Plast (2016) 0.75
Inhibition of ACE Retards Tau Hyperphosphorylation and Signs of Neuronal Degeneration in Aged Rats Subjected to Chronic Mild Stress. Biomed Res Int (2015) 0.75
Expression of central and peripheral cannabinoid receptors in human immune tissues and leukocyte subpopulations. Eur J Biochem (1995) 4.53
Measuring normal and pathological anxiety-like behaviour in mice: a review. Behav Brain Res (2001) 2.98
CB1 cannabinoid receptor knockout in mice leads to leanness, resistance to diet-induced obesity and enhanced leptin sensitivity. Int J Obes Relat Metab Disord (2004) 2.38
Selective inhibition of sucrose and ethanol intake by SR 141716, an antagonist of central cannabinoid (CB1) receptors. Psychopharmacology (Berl) (1997) 2.31
The cannabinoid CB1 receptor antagonist SR141716 increases Acrp30 mRNA expression in adipose tissue of obese fa/fa rats and in cultured adipocyte cells. Mol Pharmacol (2003) 2.12
Antidepressants recruit new neurons to improve stress response regulation. Mol Psychiatry (2011) 2.11
Activation of mitogen-activated protein kinases by stimulation of the central cannabinoid receptor CB1. Biochem J (1995) 1.93
SR141716, a central cannabinoid (CB(1)) receptor antagonist, blocks the motivational and dopamine-releasing effects of nicotine in rats. Behav Pharmacol (2002) 1.75
Biochemical and pharmacological characterisation of SR141716A, the first potent and selective brain cannabinoid receptor antagonist. Life Sci (1995) 1.68
SR 141716, a CB1 cannabinoid receptor antagonist, selectively reduces sweet food intake in marmoset. Behav Pharmacol (1998) 1.65
Cloning and expression of a complementary DNA encoding a high affinity human neurotensin receptor. FEBS Lett (1993) 1.62
Signaling pathway associated with stimulation of CB2 peripheral cannabinoid receptor. Involvement of both mitogen-activated protein kinase and induction of Krox-24 expression. Eur J Biochem (1996) 1.60
A potent and selective non-peptide antagonist of the neurokinin A (NK2) receptor. Life Sci (1992) 1.56
An amino-terminal variant of the central cannabinoid receptor resulting from alternative splicing. J Biol Chem (1995) 1.54
Cannabinoid-receptor expression in human leukocytes. Eur J Biochem (1993) 1.53
Subcellular localization of peripheral benzodiazepine receptors on human leukocytes. Lab Invest (1994) 1.50
Mouse defensive behaviors: pharmacological and behavioral assays for anxiety and panic. Neurosci Biobehav Rev (2001) 1.50
Primary structure and functional expression of mouse pituitary and human brain corticotrophin releasing factor receptors. FEBS Lett (1993) 1.48
Inhibition of long-term potentiation in rat hippocampal slices by anandamide and WIN55212-2: reversal by SR141716 A, a selective antagonist of CB1 cannabinoid receptors. Naunyn Schmiedebergs Arch Pharmacol (1995) 1.43
Improvement of memory in rodents by the selective CB1 cannabinoid receptor antagonist, SR 141716. Psychopharmacology (Berl) (1996) 1.40
Cannabinoids decrease excitatory synaptic transmission and impair long-term depression in rat cerebellar Purkinje cells. J Physiol (1998) 1.33
Functional identification of rat atypical beta-adrenoceptors by the first beta 3-selective antagonists, aryloxypropanolaminotetralins. Br J Pharmacol (1996) 1.32
Molecular cloning of a levocabastine-sensitive neurotensin binding site. FEBS Lett (1996) 1.32
Peripheral benzodiazepine binding sites: effect of PK 11195, 1-(2-chlorophenyl)-N-methyl-N-(1-methylpropyl)-3-isoquinolinecarboxamide. I. In vitro studies. Life Sci (1983) 1.31
Involvement of central cannabinoid (CB1) receptors in the establishment of place conditioning in rats. Psychopharmacology (Berl) (1998) 1.31
The immunosuppressant SR 31747 blocks cell proliferation by inhibiting a steroid isomerase in Saccharomyces cerevisiae. Mol Cell Biol (1996) 1.30
Biochemical and pharmacological properties of SR 49059, a new, potent, nonpeptide antagonist of rat and human vasopressin V1a receptors. J Clin Invest (1993) 1.28
Characterization of SR 121463A, a highly potent and selective, orally active vasopressin V2 receptor antagonist. J Clin Invest (1996) 1.28
Differentiation between two ligands for peripheral benzodiazepine binding sites, [3H]RO5-4864 and [3H]PK 11195, by thermodynamic studies. Life Sci (1983) 1.25
Molecular cloning, expression and function of the murine CB2 peripheral cannabinoid receptor. Biochim Biophys Acta (1996) 1.23
Involvement of peripheral benzodiazepine receptors in the protection of hematopoietic cells against oxygen radical damage. Blood (1996) 1.21
In vitro functional evidence of neuronal cannabinoid CB1 receptors in human ileum. Br J Pharmacol (1998) 1.18
Labelling of peripheral-type benzodiazepine binding sites in human brain with [3H]PK 11195: anatomical and subcellular distribution. Brain Res Bull (1987) 1.17
Blockade of cannabinoid CB1 receptors improves renal function, metabolic profile, and increased survival of obese Zucker rats. Kidney Int (2007) 1.14
Modulation of CB1 cannabinoid receptor functions after a long-term exposure to agonist or inverse agonist in the Chinese hamster ovary cell expression system. J Pharmacol Exp Ther (1998) 1.14
Purification and characterization of the human SR 31747A-binding protein. A nuclear membrane protein related to yeast sterol isomerase. J Biol Chem (1997) 1.13
Biochemical and pharmacological activities of SR 142948A, a new potent neurotensin receptor antagonist. J Pharmacol Exp Ther (1997) 1.12
Factor V Leiden is associated with repeated and recurrent unexplained fetal losses. Thromb Haemost (1997) 1.11
Cannabinoids enhance human B-cell growth at low nanomolar concentrations. FEBS Lett (1995) 1.10
Characterization and distribution of binding sites for [3H]-SR 141716A, a selective brain (CB1) cannabinoid receptor antagonist, in rodent brain. Life Sci (1996) 1.10
Structural features of the central cannabinoid CB1 receptor involved in the binding of the specific CB1 antagonist SR 141716A. J Biol Chem (1996) 1.09
Characterization of two cloned human CB1 cannabinoid receptor isoforms. J Pharmacol Exp Ther (1996) 1.08
Physiological effects of a lung-recruiting strategy applied during one-lung ventilation. Acta Anaesthesiol Scand (2008) 1.08
Electrophysiological and pharmacological characterization of peripheral benzodiazepine receptors in a guinea pig heart preparation. Life Sci (1984) 1.08
Distribution profile and properties of peripheral-type benzodiazepine receptors on human hemopoietic cells. Life Sci (1993) 1.06
Factor V Leiden, C > T MTHFR polymorphism and genetic susceptibility to preeclampsia. Thromb Haemost (1997) 1.05
Evidence for nerve growth factor-potentiating activities of the nonpeptidic compound SR 57746A in PC12 cells. J Neurochem (1995) 1.04
Multiple benzodiazepine receptors: evidence of dissociation between anticonflict and anticonvulsant properties by PK 8165 and PK 9084 (two quinoline derivatives). Life Sci (1981) 1.04
Labelling of "peripheral-type" benzodiazepine binding sites in the rat brain by using [3H]PK 11195, an isoquinoline carboxamide derivative: kinetic studies and autoradiographic localization. J Neurochem (1983) 1.03
Arousal-enhancing properties of the CB1 cannabinoid receptor antagonist SR 141716A in rats as assessed by electroencephalographic spectral and sleep-waking cycle analysis. Life Sci (1996) 1.03
2-Amino-6-trifluoromethoxy benzothiazole, a possible antagonist of excitatory amino acid neurotransmission--II. Biochemical properties. Neuropharmacology (1985) 1.02
SR141716, a CB1 receptor antagonist, decreases the sensitivity to the reinforcing effects of electrical brain stimulation in rats. Psychopharmacology (Berl) (2001) 1.02
Are antihistamines sedative via a blockade of brain H1 receptors? J Pharm Pharmacol (1979) 1.00
Peripheral benzodiazepine binding sites: effect of PK 11195, 1-(2-chlorophenyl)-N-methyl-(1-methylpropyl)-3 isoquinolinecarboxamide. II. In vivo studies. Life Sci (1983) 1.00
Differentiation of anxiolytic and panicolytic drugs by effects on rat and mouse defense test batteries. Neurosci Biobehav Rev (1997) 0.99
2-Amino-6-trifluoromethoxy benzothiazole, a possible antagonist of excitatory amino acid neurotransmission--I. Anticonvulsant properties. Neuropharmacology (1985) 0.98
Electrophysiological and pharmacological evidence that peripheral type benzodiazepine receptors are coupled to calcium channels in the heart. Life Sci (1985) 0.98
Reduction of opioid dependence by the CB(1) antagonist SR141716A in mice: evaluation of the interest in pharmacotherapy of opioid addiction. Br J Pharmacol (2001) 0.97
Role of tachykinins in castor oil diarrhoea in rats. Br J Pharmacol (1997) 0.97
Peripheral biological activity of SR 27897: a new potent non-peptide antagonist of CCKA receptors. Eur J Pharmacol (1993) 0.97
Peripheral benzodiazepine receptor agonists exhibit potent antiapoptotic activities. Biochem Biophys Res Commun (1999) 0.97
The rat beta 3-adrenergic receptor gene contains an intron. FEBS Lett (1993) 0.95
Effect of the nonpeptide neurotensin antagonist, SR 48692, and two enantiomeric analogs, SR 48527 and SR 49711, on neurotensin binding and contractile responses in guinea pig ileum and colon. J Pharmacol Exp Ther (1994) 0.95
Mutational analysis and molecular modelling of the antagonist SR 144528 binding site on the human cannabinoid CB(2) receptor. Eur J Pharmacol (2000) 0.95
Neurotensin is an antagonist of the human neurotensin NT2 receptor expressed in Chinese hamster ovary cells. Eur J Pharmacol (1998) 0.95
The striatal neurotensin receptor modulates striatal and pallidal glutamate and GABA release: functional evidence for a pallidal glutamate-GABA interaction via the pallidal-subthalamic nucleus loop. J Neurosci (1998) 0.95
Effects on the isolated human bronchus of SR 48968, a potent and selective nonpeptide antagonist of the neurokinin A (NK2) receptors. Am Rev Respir Dis (1992) 0.95
Functional assessment of neuronal cannabinoid receptors in the muscular layers of human ileum and colon. Dig Liver Dis (2002) 0.94
Characterization and localization of leptin receptors in the rat kidney. FEBS Lett (1997) 0.94
Neurokinin B, neurotensin, and cannabinoid receptor antagonists and Parkinson disease. Clin Neuropharmacol (2004) 0.94
Presynaptic modulation of acetylcholine, noradrenaline, and serotonin release in the hippocampus of aged rats with various levels of memory impairments. Brain Res Bull (2003) 0.93
Dual intracellular signaling pathways mediated by the human cannabinoid CB1 receptor. Eur J Pharmacol (1999) 0.92
The nonpeptide neurotensin antagonist, SR 48692, used as a tool to reveal putative neurotensin receptor subtypes. Br J Pharmacol (1994) 0.92
Identification of stereospecific [3H]spiroperidol binding sites in mammalian lymphocytes. Life Sci (1980) 0.92
Antidepressant profile in rodents of SR 58611A, a new selective agonist for atypical beta-adrenoceptors. Eur J Pharmacol (1992) 0.92
Behavioral and neurochemical changes following predatory stress in mice. Neuropharmacology (2001) 0.92
In vitro characterization of tachykinin NK2-receptors modulating motor responses of human colonic muscle strips. Br J Pharmacol (1998) 0.92
Nonpeptide vasopressin receptor antagonists: development of selective and orally active V1a, V2 and V1b receptor ligands. Prog Brain Res (2002) 0.91
Differential roles of amygdaloid nuclei in the anxiolytic- and antidepressant-like effects of the V1b receptor antagonist, SSR149415, in rats. Psychopharmacology (Berl) (2006) 0.91
Effect of mequitazine a non sedative antihistamine on brain H1 receptors. Life Sci (1981) 0.91
Immunopharmacological profile of SR 31747: in vitro and in vivo studies on humoral and cellular responses. J Neuroimmunol (1994) 0.91
Evidence for the presence of beta 3-adrenergic receptor mRNA in the human brain. Brain Res Mol Brain Res (1995) 0.91
Binding of [3H] SR 49059, a potent nonpeptide vasopressin V1a antagonist, to rat and human liver membranes. Biochem Biophys Res Commun (1994) 0.90
In vivo inhibition of endotoxin-induced pro-inflammatory cytokines production by the sigma ligand SR 31747. J Pharmacol Exp Ther (1995) 0.90
SR 48692, a non-peptide neurotensin receptor antagonist differentially affects neurotensin-induced behaviour and changes in dopaminergic transmission. Neuroscience (1994) 0.90
On the regional and specific serotonin uptake inhibition by LM 5008. Life Sci (1978) 0.90
Stimulation of cannabinoid receptor CB1 induces krox-24 expression in human astrocytoma cells. J Biol Chem (1995) 0.90
Beta-CCT, a selective BZ-omega1 receptor antagonist, blocks the anti-anxiety but not the amnesic action of chlordiazepoxide in mice. Behav Pharmacol (2000) 0.90